hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06333600, orgStudyIdInfo id: Soh-Med-23-07-05, briefTitle: Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-20, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: The trial aims to study efficay of topical vitamin D analogue in treatment of female pattern hair loss cases, conditionsModule conditions: Dermatology, conditions: Female Pattern Baldness, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Topical minoxidil, interventions name: Topical Vitamin D, interventions name: Saline spray, outcomesModule primaryOutcomes measure: Change of Sinclaire grading of Female pattern hair loss, primaryOutcomes measure: Change of Trichoscopic parameters (Hair dermoscopy), eligibilityModule sex: FEMALE, minimumAge: 15 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Facult of Medicine, Sohag Uniiversity, status: RECRUITING, city: Sohag, zip: 82515, country: Egypt, contacts name: Doaa G Abdelbaset, MSc, role: CONTACT, phone: 01022330810, phoneExt: 002, email: dodygaber64@yahoo.com, contacts name: Doaa G Abdelbaset, Msc, role: CONTACT, phone: 01014733007, phoneExt: 002, email: dodygaber64@yahoo.com, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06333587, orgStudyIdInfo id: IEO 1810, briefTitle: Minimally Invasive Treatments of the Thyroid, acronym: MIPA-MITT, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-10-10, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2035-12-31, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC), conditionsModule conditions: Papillary Thyroid Microcarcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 270, type: ESTIMATED, armsInterventionsModule interventions name: image-guided thermal ablation, outcomesModule primaryOutcomes measure: The proportion of patients with major complications occurring within one month after the date of intervention, secondaryOutcomes measure: Percentage of patients with local recurrence at 10 years, secondaryOutcomes measure: Percentage of patients with distant metastasis at 10 years, secondaryOutcomes measure: Percentage of patients died at 10 years, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Giovanni Mauri, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06333561, orgStudyIdInfo id: Liver Project 7, briefTitle: HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC., conditionsModule conditions: Hepatocellular Carcinoma, conditions: Lenvatinib, conditions: PD-1 Inhibitor, conditions: Hepatic Arterial Infusion Chemotherapy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Hepatic arterial infusion chemotherapy, interventions name: Lenvatinib, interventions name: Tislelizumab, interventions name: Toripalimab, interventions name: Sintilimab, interventions name: Camrelizumab, outcomesModule primaryOutcomes measure: Overall survival, secondaryOutcomes measure: Progression-Free-Survival, otherOutcomes measure: Objective response rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese PLA General hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100853, country: China, contacts name: Qunfang Zhou, Md, role: CONTACT, phone: 8619868000115, email: zhouqun988509@163.com, contacts name: Feng Duan, MD, role: CONTACT, phone: 8613910984586, email: duanfeng@vip.sina.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06333548, orgStudyIdInfo id: KSH_MB_2024_1, briefTitle: Cord Blood Alarin Levels in Term Babies, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-18, primaryCompletionDateStruct date: 2023-12-23, completionDateStruct date: 2024-01-15, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Konya City Hospital, class: OTHER, descriptionModule briefSummary: In this study, alarin levels in the cord blood of babies with large birth weights will be compared with babies of normal weight. Thus, the investigators aimed to find out whether there is a relationship between babies' birth weights and alarin., conditionsModule conditions: Birth Weight, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 87, type: ACTUAL, armsInterventionsModule interventions name: Appropriate for gestational age, small for gestational age, large for gestational age, Baby of mother diagnosed with GDM, outcomesModule primaryOutcomes measure: Comparison of cord blood alarin levels of babies in different groups according to birth weight (low-appropriate-large) and babies of mothers diagnosed with gestational diabetes regardless of birth weight., eligibilityModule sex: ALL, minimumAge: 1 Minute, maximumAge: 5 Minutes, stdAges: CHILD, contactsLocationsModule locations facility: MELEK, city: Konya, state: Sıhhiye, zip: 06100, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06333535, orgStudyIdInfo id: 2022/568, briefTitle: Foot and Abdominal Massage Applied to After Colonoscopy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-01-01, completionDateStruct date: 2024-02-25, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: TC Erciyes University, class: OTHER, descriptionModule briefSummary: The aim of this study was to determine the effect of foot and abdominal massage applied to after colonoscopy on abdominal distention, pain and patient satisfaction.This was a randomized controlled experimental study conducted at the Colonoscopy unit in Medica Faculty Hospital . Participants assigned to the intervention group-1 received foot massages after colonoscopy, participants assigned to the intervention group-2 received abdominal massages after colonoscopy and participants assigned to the intervention group-3 received foot and abdominal massages after colonoscopy. Participants assigned to the control group received only "routine care" after colonoscopy. The abdominal pain, distension and satisfaction levels of the patients evaluated using the Numerical Rating Scale, conditionsModule conditions: Abdominal Pain, conditions: Distention, conditions: Satisfaction, Patient, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 96, type: ACTUAL, armsInterventionsModule interventions name: foot massage, interventions name: abdominal massage, interventions name: foot and abdominal massage, outcomesModule primaryOutcomes measure: abdominal pain, primaryOutcomes measure: Abdominal distension, primaryOutcomes measure: Patient Satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erciyes University, city: Kayseri, zip: 38000, country: Turkey, geoPoint lat: 38.73222, lon: 35.48528, hasResults: False
protocolSection identificationModule nctId: NCT06333522, orgStudyIdInfo id: 23-00979, briefTitle: Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-01-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: NYU Langone Health, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine the effect of Losartan, an Angiotensin II Receptor Blocker (ARB), on the formation development of arthrofibrosis in patients who have had a primary total knee arthroplasty. This study aims to assess the post-operative range of motion and the incidence of MUA within three months following the index arthroplasty in the treatment arm (losartan) and the control arm., conditionsModule conditions: Arthrofibrosis of Knee, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Losartan, outcomesModule primaryOutcomes measure: Change in range of motion, primaryOutcomes measure: Rate of manipulation under anesthesia (MUA) after elective total knee arthroplasty, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: NYU Langone Health, city: New York, state: New York, zip: 10016, country: United States, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06333509, orgStudyIdInfo id: CT071-HM-01, briefTitle: Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-06-15, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: CARsgen Therapeutics Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia., conditionsModule conditions: Multiple Myeloma, conditions: Primary Plasma Cell Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Phase 1; Dose escalation followed by dose expansion Phase 2; Single group of each indication will be dosed at the recommended dose level from Phase 1., primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: N/Ap, enrollmentInfo count: 166, type: ESTIMATED, armsInterventionsModule interventions name: CT071, outcomesModule primaryOutcomes measure: Phase 1: Evaluation of the Safety of CT071 and determination of Maximum Tolerated Dose (MTD)., primaryOutcomes measure: Phase 2: Objective response rate, secondaryOutcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes, secondaryOutcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes, secondaryOutcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes, secondaryOutcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes, secondaryOutcomes measure: Phase 2: Evaluate additional Safety of CT071., secondaryOutcomes measure: Phase 1 and 2: Assess immunogenicity of CT071, secondaryOutcomes measure: Phase 1 and 2: Evaluate PK profile of CT071, secondaryOutcomes measure: Phase 1 and 2: Evaluate PK profile of CT071, secondaryOutcomes measure: Phase 1 and 2: Evaluate PK profile of CT071, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06333496, orgStudyIdInfo id: AB20240102H, briefTitle: Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-02, primaryCompletionDateStruct date: 2024-03-29, completionDateStruct date: 2024-04-08, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Alpine Biotech LLC, class: INDUSTRY, descriptionModule briefSummary: BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula.SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints., conditionsModule conditions: Blood Sugar; High, conditions: Overweight and Obesity, conditions: Fat Burn, conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: GLP1 Booster (GB), outcomesModule primaryOutcomes measure: blood glucose level, primaryOutcomes measure: blood HbA1c level, primaryOutcomes measure: blood insulin level, primaryOutcomes measure: blood GLP1 level, primaryOutcomes measure: blood cholesterol level, primaryOutcomes measure: body weight, primaryOutcomes measure: body fat mass, primaryOutcomes measure: body lean mass, primaryOutcomes measure: body mass index, primaryOutcomes measure: body fat index, primaryOutcomes measure: waist hip ratio, secondaryOutcomes measure: Satiety score, secondaryOutcomes measure: Resting metabolic rate, secondaryOutcomes measure: Blood pressure, secondaryOutcomes measure: Heart rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Alpine Bio, city: Salt Lake City, state: Utah, zip: 84109, country: United States, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06333483, orgStudyIdInfo id: AUTO1-SL1, secondaryIdInfos id: 2023-508236-60-00, type: CTIS, briefTitle: A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE), acronym: CARLYSE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-02, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Autolus Limited, class: INDUSTRY, descriptionModule briefSummary: This is a Phase I study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE., conditionsModule conditions: Systemic Lupus Erythematosus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Obecabtagene autoleucel (obe-cel), outcomesModule primaryOutcomes measure: Dose limiting toxicities, primaryOutcomes measure: Adverse events, secondaryOutcomes measure: Remission rate according to Definition of Remission in SLE (DORIS), secondaryOutcomes measure: Response over time according to Definition of Remission in SLE (DORIS), secondaryOutcomes measure: Time to response according to Definition of Remission in SLE (DORIS), secondaryOutcomes measure: Change over time in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), secondaryOutcomes measure: Change over time in Physician's global assessment (PGA), secondaryOutcomes measure: Pharmacokinetics (maximum serum concentration [Cmax]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood, secondaryOutcomes measure: Pharmacokinetics (time to reaching maximum serum concentration [Tmax]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood, secondaryOutcomes measure: Pharmacokinetics (area under the curve [AUC]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood, secondaryOutcomes measure: Pharmacokinetics (last observed quantifiable concentration [Clast]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood, secondaryOutcomes measure: Pharmacokinetics (time to reach last observed quantifiable concentration [Tlast]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood, secondaryOutcomes measure: Pharmacodynamics: B cell aplasia, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University College London Hospitals NHS Foundation Trust, status: RECRUITING, city: London, country: United Kingdom, contacts name: Maria Leandro, role: CONTACT, email: uclh.car-ttrials@nhs.net, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06333470, orgStudyIdInfo id: 2024KYPJ025, briefTitle: Liwan Eye Study: the Fourth Follow-up, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Zhongshan Ophthalmic Center, Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: Primary angle-closure glaucoma (PACG) is one of the major causes of blindness affecting more than 20 million patients worldwide. The goals of this observational cohort study are to investigate the 20-year incidence of PACG in Chinese population aged 50 years and to develop prediction models for the long-term risk of progression from primary angle-closure suspect (PACS) to PACG., conditionsModule conditions: Primary Angle-Closure Glaucoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Primary angle closure diseases, outcomesModule primaryOutcomes measure: The 20-year incidence of primary angle-closure glaucoma (PACG) in Chinese population aged over 50 years, secondaryOutcomes measure: The development of prediction models for the long-term risk of progression from primary angle-closure suspect (PACS) to primary angle-closure glaucoma (PACG), secondaryOutcomes measure: The 20-year incidence of visual impairment in Chinese population aged over 50 years, eligibilityModule sex: ALL, minimumAge: 70 Years, maximumAge: 100 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06333457, orgStudyIdInfo id: EA4/024/24, briefTitle: Presence and Relapse Rates in Patients With Alcohol Use Disorder Using Virtual Reality, acronym: PRE-VR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Charite University, Berlin, Germany, class: OTHER, descriptionModule briefSummary: Investigation of the influence of the sense of presence during a Virtual Reality Cue-Exposure Therapy (VR-CET) with alcohol-associated cues on craving and relapse rates.Study group: abstinent patients (at least 18 years old) with a diagnosed alcohol dependence after completed inpatient withdrawal treatment in the the last 3 months.Primary hypothesis: the experience of presence during a virtual presentation of alcohol in alcohol-dependent patients is associated with levels of craving for alcohol during VR-CET., conditionsModule conditions: Alcohol Dependence, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: VR Cue-Exposure Therapy, outcomesModule primaryOutcomes measure: Craving, primaryOutcomes measure: Craving, primaryOutcomes measure: Craving, secondaryOutcomes measure: Relapse rates, secondaryOutcomes measure: Quality of Life, secondaryOutcomes measure: Motion Sickness, secondaryOutcomes measure: Presence in VR, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Psychiatric University Hospital Charité at St. Hedwig Hospital, city: Berlin, zip: 10115, country: Germany, geoPoint lat: 52.52437, lon: 13.41053, hasResults: False